Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus
B D Gaynor1, K A Holbrook, J P Whitcher
1The Francis I Proctor Foundation and the Department of Ophthalmology, University of California, San Francisco, 94143, USA. bgaynor@itsa.ucsf.edu
Aims:
To determine if macrolide resistant Streptococcus pneumoniae will be a major concern in areas that receive annual mass azithromycin distributions for trachoma.
Methods:
A cross sectional survey was conducted of nasopharyngeal S pneumoniae isolates for susceptibility to azithromycin 1 year after administering a single dose of azithromycin to treat trachoma in a village in Nepal.
Results:
S pneumoniae was isolated from 50 (86%) of 57 nasopharyngeal cultures and no resistance to azithromycin was detected.
Conclusion:
The authors were unable to demonstrate that mass azithromycin therapy for trachoma produced macrolide resistant S pneumoniae that persists until the next scheduled annual treatment.
More Related Videos
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Microbiota Modulation by Antibiotics
Atypical Pneumonia
Mechanism of Antibiotic Resistance in MRSA
Trichomoniasis
Clinical Significance of Antibiotic Resistance


